Trials / NCT07807111
Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy
Recruiting now Phase 1 / Phase 2 Gene therapy
- Sponsor
- SparingVision
- Treatment
- SPVN20 (high dose); SPVN20 (medium dose); SPVN20 (low dose)
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa (RP), Rod Cone Dystrophy
- Ages
- 18 Years to no upper limit
- Enrollment
- 27 participants
- Started
- 2025-10-08
- Main results expected
- 2032-03
- Results posted
- Not yet
- Record last updated
- 2026-09-08
What the study is testing
This open-label, multi-center study is to evaluate the safety, tolerability, and efficacy of escalating doses of a gene therapy called SPVN20 administered via a single intravitreal injection in participants with advanced Rod-Cone Dystrophy.
Where it runs
Belgium (1)
- Ghent University Hospital, Ghent (recruiting now)
France (1)
- CHNO XV-XX Paris - CIC 1423, Paris (recruiting now)
Ireland (1)
- Royal Victoria Eye And Ear Hospital, Dublin (recruiting now)